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Bioluminescence resonance energy transfer (BRET) is an improved version of earlier res-
onance energy transfer technologies used for the analysis of biomolecular protein inter-
action. BRET analysis can be applied to many transmembrane receptor classes, however
the majority of the early published literature on BRET has focused on G protein-coupled
receptor (GPCR) research. In contrast, there is limited scientific literature using BRET to
investigate receptor tyrosine kinase (RTK) activity.This limited investigation is surprising as
RTKs often employ dimerization as a key factor in their activation, as well as being important
therapeutic targets in medicine, especially in the cases of cancer, diabetes, neurodegener-
ative, and respiratory conditions. In this review, we consider an array of studies pertinent to
RTKs and other non-GPCR receptor protein–protein signaling interactions; more specifically
we discuss receptor-protein interactions involved in the transmission of signaling commu-
nication. We have provided an overview of functional BRET studies associated with the
RTK superfamily involving: neurotrophic receptors [e.g., tropomyosin-related kinase (Trk)
and p75 neurotrophin receptor (p75NTR)]; insulinotropic receptors [e.g., insulin receptor
(IR) and insulin-like growth factor receptor (IGFR)] and growth factor receptors [e.g., ErbB
receptors including the EGFR, the fibroblast growth factor receptor (FGFR), the vascular
endothelial growth factor receptor (VEGFR) and the c-kit and platelet-derived growth fac-
tor receptor (PDGFR)]. In addition, we review BRET-mediated studies of other tyrosine
kinase-associated receptors including cytokine receptors, i.e., leptin receptor (OB-R) and
the growth hormone receptor (GHR). It is clear even from the relatively sparse experimen-
tal RTK BRET evidence that there is tremendous potential for this technological application
for the functional investigation of RTK biology.
Keywords: receptor tyrosine kinase, RTK, protein–protein interaction, neurotrophic, insulin receptor, insulin-like
growth factor receptor, epidermal growth factor receptor, cytokine receptors
INTRODUCTION
As a natural phenomenon, bioluminescence is found in marine
animals such as the sea pansy Renilla reniformis and the
jellyfish Aequorea victoria. Research has demonstrated that the
oxidation of the intrinsically produced substrate coelenter-
azine to coelenteramide initializes the bioluminescence in those
Abbreviations: Å, Angstrom; AD, Alzheimer’s disease; APP, amyloid precursor
protein;α(v)β(3), alpha(v)beta(3) (integrins); β2AR,β2-adrenergic receptor; BDNF,
brain-derived neurotrophic factor; BRET, bioluminescence resonance energy trans-
fer; cAMP, cyclic adenosine monophosphate; COPD, chronic obstructive pulmonary
disorder; EGF, epidermal growth factor; EGFR, epidermal growth factor recep-
tor; ErbB4, erythroblastic leukemia viral (v-erb-b) oncogene homolog 4; EYFP,
enhanced yellow fluorescent protein; FAK, focal adhesion kinase; FGF, fibrob-
last growth factor; FGFR, fibroblast growth factor receptor; FRET, fluorescence
resonance energy transfer; GFP, green fluorescent protein; GFP/YFP, green fluores-
cent protein/yellow fluorescent protein; GHR, growth hormone receptor; GPCR,
G protein-coupled receptor; Grb, growth factor receptor-bound protein; HCS,
high-content screening; HD, Huntington’s disease; HRG-β1, heregulin beta1; IGF,
insulin-like growth factor; IGF-1R, insulin-like growth factor-1 receptor; IGFR,
insulin-like growth factor; IL-1β, Interleukin-1 beta; IR, insulin receptor; IRA,
insulin receptor alpha subunit; IRB, insulin receptor beta subunit; IRS, insulin
receptor substrate; Jak, Janus kinase; Jak/STAT, Janus kinases/signal transducers
organisms (Figure 1) (Hart et al., 1978; Pfleger and Eidne,
2003). Bioluminescence resonance energy transfer (BRET) simply
represents an energy transfer from a luminescent donor to a flu-
orescent acceptor, which re-emits light at another wavelength.
BRET requires a sufficient overlap between the emission spec-
trum of a donor molecule and the absorption spectrum of an
acceptor molecule (Figure 1) (Issad et al., 2002). BRET also
and activators of transcription; Kit, kit receptor; NGF, nerve growth factor; NT-
3, neurotrophin-3; OB-R, leptin receptor; p75NTR, p75 neurotrophin receptor;
p85, PI3Kinase 85kd subunit; PDGF, platelet-derived growth factor; PDGF-BB,
platelet-derived growth factor beta polypeptide; PDGFR, platelet-derived growth
factor receptor; PDGFRA, platelet-derived growth factor receptor, alpha polypep-
tide; PDGFRB, platelet-derived growth factor receptor, beta polypeptide; PIP3,
phosphatidylinositol-3 phosphate; PKA, protein kinase A; PLCγ1, phospholipase
C gamma 1; PTB, phosphotyrosine binding; PTP1B, protein tyrosine phosphatase
1B; Pyk2, proline-rich tyrosine kinase 2; Rluc, Renilla luciferase; RTK, receptor
tyrosine kinase; SCF, stem cell factor; SH2, Src-homology 2; Shc, adaptor pro-
tein 46; Socs, silencers of cytokine signaling; STAT, signal transducer and activator
of transcription; Stat5a, signal transducer and activator of transcription 5a; Trk,
tropomyosin-related kinase; VEGF, vascular endothelial growth factor; VEGF-C,
vascular endothelial growth factor-C; VEGFR, vascular endothelial growth factor
receptor.
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FIGURE 1 |The BRET assay has been developed to study
protein–protein interactions. In an example of studying the interaction
between protein A and protein B using the BRET assay, fusion proteins
with Rluc and YFP are coexpressed, and luminescent signals are measured
at 480 nm (Rluc light emission) and 530 nm (YFP light emission) upon
addition of the Rluc substrate coelenterazine. If protein A does not interact
with protein B and if Rluc and YFP are not at a BRET-permissive distance
(>100 Å) and orientation, non-radioactive light emission is mainly measured
at 480 nm. If protein A is in close proximity, or interacts with, protein B,
placing Rluc and YFP at a BRET-permissive distance (<100 Å) and
orientation, non-radioactive energy transfer can be measured at an
increased light emission at 530 nm.
depends on the distance between the donor and the acceptor,
which should be in the range of 10–100 Å, and on their inter-
acting orientation (Figure 1) (Wu and Brand, 1994). Based on this
principle, the BRET assay has been developed and applied to study
protein–protein interactions as a facile methodological tool.
An important advantage of the BRET assay is that it allows
researchers to study dynamic protein–protein interactions in liv-
ing cells (Hamdan et al., 2006). In general, BRET assays involve
proteins of interest fused with either a donor molecule (Renilla
luciferase, or Rluc) or an acceptor molecule [usually a variant
of green fluorescent protein (GFP)/enhanced yellow fluorescent
protein (EYFP)]. BRET fusion proteins are created by expressing
specifically engineered cDNAs from both the protein of interest
and the donor or acceptor molecule. Subsequently, both donor-
tagged and acceptor-tagged constructs are co-transfected into host
cells. The presence of energy transfer between the donor and
acceptor molecules can then be measured. The amount of energy
transference correlates with the extent to which the specific tagged
molecules exist within proximity of each other. The wavelengths
for detection differ according to the use of BRET (480 nm for Rluc
and 530 nm for EYFP) (Figure 1). The original BRET technol-
ogy generally used EYFP as an acceptor, a red-shifted variant of
YFP that has an emission maximum at 530 nm. In contrast, the
recently introduced BRET-2 uses a codon of humanized wild-type
GFP form, termed GFP2. GFP2 has a maximal emission at 510 nm.
The BRET-2 system is designed to increase the spectral resolu-
tion compared to the original BRET technology. The improved
resolution is attributed to the application of DeepBlue C coelen-
terazine with Rluc and GFP2, resulting in better separation of the
luciferase/DeepBlue and GFP2 emission peaks. Whereas, in the
original BRET technology, the h form of coelenterazine with Rluc
and EYFP is used (Pfleger and Eidne, 2003). However, one of the
limitations of BRET-2 is its lower efficiency of light emission that
implies overexpression of the partners at supraphysiological levels.
Unlike fluorescence resonance energy transfer (FRET), BRET-
based systems do not require the excitation of the donor with
an external light source thus, minimizing the unnecessary aut-
ofluorescence, light scattering, photobleaching, and the possible
photoisomerization of the donor, or even photodamage to the
cells. BRET also allows detection of smaller variations in BRET
signals as there is low background in the BRET assays due to the
absence of any contamination of the light output. Ratiometric
measurements of BRET minimize any variations that may occur
due to a wide variety of possibilities including: differences in assay
volumes, cell types, and numbers, as well as a decay of a sig-
nal in a given plate. As with other bioluminescence-based assays,
BRET performance can be significantly affected by several factors,
including the spectral properties of donor and acceptor mole-
cules (Xu et al., 1999), the ratio of donor to acceptor molecules
(Gomes et al., 2002), the distance and orientation of the mole-
cules of interest (Wu and Brand, 1994; Kenworthy, 2001) and the
strength and stability of the interactions (Pfleger and Eidne, 2003).
Therefore, while presenting multiple advances over previous tech-
nologies such as FRET, BRET-based approaches can have their
functional limitations. Using BRET to study protein–protein inter-
actions may be critiqued for providing a potentially skewed view
of biomolecular interactions. Biomolecular complexes are likely to
contain tens or even hundreds of proteins at times and due to the
relatively limited number of BRET probes, the number of simulta-
neous interactions that can be monitored is worryingly limited. As
BRET employs ectopically expressed factors there is also an issue
of both the lack of endogenous regulation of expression, cellular
disposition, and compartmentalization of the factor. Expressing a
novel factor in a cell line is highly likely to disrupt the stoichiometry
of multiple signaling systems with potentially unknown conse-
quences (Martin et al., 2009a). In addition to this, the variable
nature of the host-cell environment, e.g., passage number, differ-
entiation methodologies or viral transformation, will also likely
affect signaling systems investigated using ectopically expressed
BRET probes. Ideally, molecular interactions should be studied
with native-state proteins as the addition of BRET labels may also
affect the physico-chemical properties of the protein which may
change its transport between different cell compartments, its post-
translational modification status, its protein–protein interactions,
and even its degradative processing. Changes to any of these prop-
erties of the target protein will likely have a significant impact on
its perceived functionality using the BRET technique.
The BRET assay was first described in a study on the dimeriza-
tion of the bacterial Kai B clock protein (Xu et al., 1999). Prior to
this first BRET demonstration, non-BRET bioluminescent tech-
nologies were employed by Barak et al. (1997) to investigate the
functional signaling activity of G protein-coupled receptors via
β-arrestin-GFP translocation to the plasma membrane. Follow-
ing this, a considerable body of BRET-based G protein-coupled
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receptor (GPCR) functional analysis has now been generated
(Angers et al., 2000; Galés et al., 2005; Ayoub et al., 2007). In
addition, the activation or inactivation of second messengers such
as cyclic adenosine monophosphate (cAMP) generated by GPCR
activation, has also been well-studied using BRET. These tech-
niques include the fusion of the regulatory and catalytic subunits
of protein kinase A (PKA) to GFP and Rluc biosensors in order
to monitor cAMP activity (Prinz et al., 2006), or the fusion of
biosensors to the guanine nucleotide exchange protein activated by
cAMP (Jiang et al., 2007; Barak et al., 2008). While BRET has been
exhaustively employed for GPCR-based studies, in this present
review, we instead focus on the applications of the BRET assays in
the functional investigations of the receptor tyrosine kinase (RTK)
superfamily. This superfamily contains a variety of distinct recep-
tors associated with diverse functional activities. Hence, the RTK
superfamily includes neurotrophic receptors such as tropomyosin-
related kinase (Trk) and p75 neurotrophin receptor (p75NTR),
insulinotropic receptors including the insulin receptor (IR) and
insulin-like growth factor receptor (IGFR), as well as growth
factor receptors such as the ErbB receptors including the epider-
mal growth factor receptor (EGFR), the fibroblast growth factor
receptor (FGFR), the vascular endothelial growth factor receptor
(VEGFR), and the c-kit and platelet-derived growth factor recep-
tor (PDGFR). Cytokine receptors, e.g., leptin and growth hormone
receptors (GHR), while not being traditional RTKs, possess mul-
tiple functional similarities with RTKs, e.g., receptor dimerization
tyrosine kinase usage, and as such have also been investigated with
BRET-based approaches.
INVESTIGATING GPCR SIGNALING WITH BRET
Bioluminescence resonance energy transfer approaches have been
extensively applied to the investigation of the dimerization or
other protein–protein interactions of multiple types of GPCRs,
e.g., melatonin receptors (Ayoub et al., 2002), chemokine recep-
tors (CXCR1, 2, and 4 and CCR2 and 5) (Milligan et al., 2005),
α/β-adrenergic receptors (Angers et al., 2000; Small et al., 2006),
cholecystokinin receptors (Harikumar et al., 2006), yeast α-factor
receptors (Gehret et al., 2006), opsin receptors (Vrecl et al., 2006),
protease-activated receptor 1 (Ayoub et al., 2012), and secretin
receptors (Lisenbee and Miller, 2006). BRET has also been used
to study the ability of muscarinic acetylcholine receptors, M3 and
M5, to form homo- and hetero-dimers in living cells in a manner
independent of receptor activation (Borroto-Escuela et al., 2010).
As mentioned previously, one of the earliest BRET studies was
used to assess whether the human β2-adrenergic receptor (β2AR),
existed as a homodimer in living cells (Angers et al., 2000). This
study found that GPCRs exist as functional dimers in the in vivo
setting and therefore, BRET-based assays could be applied for
the study of both constitutive and hormone-promoted selective
protein–protein interactions (Angers et al., 2000). In addition to
GPCR–GPCR interactions, both membrane and cytosolic protein
interaction with GPCRs have been studied with BRET (Milligan,
2004; Pfleger and Eidne, 2005; Pfleger et al., 2006). For exam-
ple, BRET1-based β-arrestin 2 translocation assays have been
used to quantify receptor activation/inhibition (Hamdan et al.,
2005). The BRET1 experimental approach is commonly used
when it is important to maintain a systemic physiological protein
expression level (Bacart et al., 2008). One pertinent study describes
a BRET1-β-arrestin recruitment assay in stable mammalian cells
and its successful application in high-throughput screening for
GPCR antagonists (Hamdan et al., 2005).
INVESTIGATING TYROSINE KINASE-BASED RECEPTOR
SYSTEMSWITH BRET
While GPCRs form perhaps the most important pharmacother-
apeutic target for drug research (Maudsley et al., 2005) it is still
crucial to generate a diversity of therapeutic strategies to con-
tend with disease pathophysiologies. Therefore, the development
of RTK-based drug discovery is vital to support the already mature
field of GPCR-based drug design. In addition to the important
use of BRET-based techniques for GPCR research, BRET has also
proven to be useful in monitoring RTK receptor functionality and
assisting in drug discovery efforts for identifying novel RTK mod-
ulators (Tan et al., 2007). BRET has also been used to study the
nature of the ligand-induced conformational changes that accom-
pany signal transduction pathway activation in RTKs (Boute et al.,
2001).
Receptor tyrosine kinases are a varied group of transmem-
brane proteins acting as receptors for cytokines, growth factors,
hormones, and other signaling molecules. RTKs are expressed in
many cell types and play important roles in a wide variety of
cellular processes, including growth, differentiation, and angio-
genesis. Many RTKs, characterized by the archetypical EGFR,
are composed of a single transmembrane helical region, a large
extracellular immunoglobulin-like N-terminal domain and an
intracellular C-terminal domain possessing an intrinsic tyro-
sine kinase activity. Cytokine receptors, while not possessing an
intrinsic tyrosine kinase activity in their C-terminal domain, do
actively recruit Janus kinase (Jak) family tyrosine kinase mole-
cules to their intracellular domain to effect downstream signal
transduction. Receptor dimerization, either ligand-driven or con-
stitutive, forms an important component of the activation process
of RTKs. These phenomena, therefore, make the investigation
of their functionality with BRET highly analogous to the use
of BRET in GPCR studies. Ligand-mediated RTK dimerization,
e.g., for EGFR or PDGFR, or constitutive dimerization, e.g., for
insulin/insulin-like growth factor-1 receptor, results in the stim-
ulation of either tyrosine kinase recruitment (Jak2) or activation
of intrinsic tyrosine kinase activity (EGFR). These active tyrosine
kinases can then phosphorylate downstream signaling molecules
as well as the opposing dimer unit of the RTK (auto-tyrosine phos-
phorylation). These auto-tyrosine phosphorylation sites conform
to the C-terminal domain of the RTK into a series of high-
affinity binding sites for downstream signaling proteins which
possess canonical Src-homology 2 (SH2) or protein phosphotyro-
sine binding (PTB) motifs. The assembly of multiple proteins with
the C-terminal domain of the RTKs then serves to propagate and
“condition” the downstream signaling of the receptor (Maudsley
et al., 2000b; Martin et al., 2009a). A significant advancement in the
appreciation of functional transmembrane receptor systems was
made by Maudsley et al. (2000a,b) through their demonstration
of the creation of “higher-order” multi-protein signaling entities
between active GPCRs and RTKs. The discovery that GPCR-based
signals can then merge and also condition RTK-mediated signaling
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has since been developed into an important field of research into
the nature of receptor signaling transfer for many receptor systems
(Gschwind et al., 2001; Sabri et al., 2002; Piiper et al., 2003; Sales
et al., 2004; Flajolet et al., 2008; Chadwick et al., 2011a). This pro-
ductive interaction therefore opens up the potentially important
application of BRET-based techniques for the investigation of this
emerging paradigm in receptor biology. Eventually it is likely that
with BRET-mediated high-content screening (HCS) techniques,
receptor ligands possessing a predilection for activating this RTK-
associated GPCR “ensemble” may be rationally discovered and
therefore constitute a novel and unique pharmacological resource
(Maudsley et al., 2005). In the following sections of this review, we
will discuss the most recently developed experimental evidence
and concepts derived from RTK-associated BRET research. Each
of the target receptor systems is likely to represent some of the most
important future therapeutic targets, given the need for increased
diversity in therapeutic mechanisms for the future pharmacopeia.
BRET FOR LABELING OF NEUROTROPHIC RECEPTORS
The neurotrophins are a family of closely related signaling proteins
that control a number of crucial aspects of neuronal (both central
and peripheral) activity, i.e., survival, development, responses to
stress, and synaptic reinforcement (Mattson et al., 2004a; Skaper,
2008; Stranahan et al., 2009; Golden et al., 2010; Chadwick et al.,
2011b; Driscoll et al., 2012). In mammals, the Trk subfamily of
RTKs constitutes one major class of neurotrophic tyrosine kinase
receptors. Sharing the typical features of RTKs, the activation of
Trk receptors is often triggered by neurotrophin-mediated dimer-
ization and/or transphosphorylation of an activation loop kinase
(Huang and Reichardt, 2003). Most mammalian neurotrophins
elicit their biological functions by activating one or more of the
three members of the Trk family of RTKs (TrkA, TrkB, and TrkC)
(Kaplan et al., 1991; Klein et al., 1991; Lamballe et al., 1991; Chad-
wick et al., 2010; Park et al., 2011). Being able to accurately monitor
Trk activities in living cells will likely provide a platform for both
drug development and mechanism-based research.
Based on the original BRET technology, Tan et al. (2007) further
developed BRET-2 assays specifically for evaluating the interac-
tions between Trk receptors (TrkA, TrkB, TrkC) and three kinds of
effectors (p85, Shc46, phospholipase C gamma, PLCγ1) with three
different neurotrophic stimulators (nerve growth factor, NGF,
brain-derived neurotrophic factor, BDNF, neurotrophin-3, NT-
3). To briefly describe the BRET-2 process, the size of the BRET-2
signal is expressed as the ratio of GFP2 and luciferase emissions,
which correlates with the extent of recruitment of the effector pro-
teins to the Trks, once Trks are activated. Under the stimulation of
agonists including NGF (TrkA), BDNF (TrkB), and NT-3 (TrkC),
interactions of TrkA-p85/Shc46/PLCγ1, TrkB-p85/Shc46/PLCγ1,
and TrkC-Shc46 were continuously monitored, generating both
BRET-2 ratio/log [concentration] curves as well as the EC50 for
each ligand. Similarly, under the inhibition with the antagonist
K252a, the same recruiting interactions were also captured, gen-
erating IC50 values, as well. All together, using BRET-2, this group
successfully demonstrated that multiple forms of Trk activity can
be investigated in live cells and may represent a reliable core tech-
nology for evaluating Trk activity and responsiveness to novel
therapeutics.
The BRET assay-based monitoring system has also been used to
answer several conformational and mechanistic questions related
to functions of Trk receptors. Overexpression of TrkB has been
linked to neuroblastomas (Brodeur, 2003) as well as other types
of cancers (Moon et al., 2011; Fujikawa et al., 2012). TrkB kinase
activity has also been shown to be responsible for the induction
of metastasis by the suppression of anoikis, a form of apopto-
sis due to incorrect or inadequate cell and extracellular matrix
attachment (Douma et al., 2004). Additionally, a growing body of
evidence demonstrates that TrkB-mediated BDNF signaling plays
a critical role in the pathogenesis of multiple neurodegenerative
disorders such Alzheimer’s disease (AD) and Huntington’s dis-
ease (Martin et al., 2009b, 2012; Chadwick et al., 2011b; Cong
et al., 2012). With the application of the BRET assay, De Vries
et al. (2010) demonstrated a conformational rearrangement of
preformed TrkB/Shc complexes initialized by BDNF-dependent
activation, revealing a complex level of interaction between TrkB
and Shc. It is noteworthy that in the study by De Vries et al. (2010),
both TrkB receptor mutants as well as compound blockers were
tested with the BRET assay. Therefore again, this further suggests
that the TrkB BRET assay could be utilized to investigate Trk
signaling and potential therapeutic design and provides a good
example for the BRET assay application in labeling neurotrophic
receptors. This study highlights the application of the BRET satu-
ration assay which allows the determination of a conformational
rearrangement of preformed complexes versus the recruitment of
one signaling molecule to another, the latter being indicative of
the relative affinity of two interacting molecules. This application
has also been highlighted in earlier studies (Lacasa et al., 2005;
Nouaille et al., 2006).
The p75NTR, a C-terminally truncated, non-signaling Trk
receptor modulator (Segal, 2003; Makkerh et al., 2005) is involved
in the regulation of multiple neuronal activities, e.g., develop-
ment of neurodevelopmental processes (Nykjaer et al., 2005),
neuronal migration (Johnston et al., 2007; Snapyan et al., 2009),
and also neuronal growth inhibition (Yamashita et al., 1999; von
Schack et al., 2001). Physically p75NTR can potentiate Trk signal-
ing by potentiating neurotrophin ligand binding to TrkA recep-
tors (Barker and Shooter, 1994; Hantzopoulos et al., 1994) thus
enhancing cellular neurotrophin sensitivity (Yamashita et al., 1999;
von Schack et al., 2001; Ito et al., 2003). The BRET assay has also
been used for studying the interactions between the amyloid pre-
cursor protein, that is strongly implicated in AD pathophysiology,
and p75NTR (Fombonne et al., 2009). Based on the BRET results,
the connection between amyloid precursor protein and p75NTR
is one of the most selective interactions observed in AD.
BRET ASSAY FOR LABELING INSULINOTROPIC RECEPTORS
Insulin, a complex peptide hormone secreted by the beta cells of
the Islets of Langerhans in the pancreas, controls energy metab-
olism in the liver, muscle, and adipose tissue by binding to its
cognate transmembrane tyrosine kinase receptor, i.e., the IR. Alter-
ations in insulin signaling and action lead to pathophysiological
conditions such as obesity, Type 2 diabetes mellitus (T2DM), and
generalized metabolic syndrome (Maudsley et al., 2011). The IR
is composed of two extracellular alpha-chains that bind ligands
and two transmembrane and intracellular β-subunit chains that
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possess the tyrosine kinase activity. The IR can be considered to
be a “pre-dimerized” analog of growth factor receptors such as the
EGFR. While the IR is effectively dimerized before the interaction
with the peptide ligand, binding of insulin induces a conforma-
tional change that allows transphosphorylation of one β-subunit
of the IR by the ligand-mediated stimulation of the intrinsic
tyrosine kinase activity of the other β-subunit. BRET assays are
highly sensitive for quantifying ligand-independent (constitutive),
agonist-induced or antagonist-inhibited RTK activity levels (Tan
et al., 2007). The first use of BRET to quantify constitutive, agonist-
induced and antagonist-induced RTK activity was performed by
Boute et al. (2001), using hormones, growth factors, as well as
monoclonal antibodies (Boute et al., 2001). Blanquart et al. (2008)
have utilized BRET to characterize ligand-induced conformational
changes that occur within hybrids of IRA/IRB, the two isoforms
of IR either containing or not containing exon 11 (Blanquart
et al., 2008). IRA/IRB hybrids have been reported to be produced
randomly in cells (Blanquart et al., 2008).
The discovery of pharmacological agents that specifically acti-
vate the tyrosine kinase activity of the IR will be of great impor-
tance for the treatment of insulin-resistant or insulin-deficient
patients. As functional homologs to insulin, the insulin-like
growth factors (IGF-I and IGF-II) play important roles in reg-
ulating growth, development, and differentiation of cells (Dupont
and LeRoith, 2001) by binding to their cognate IGF-I receptor
(IGF-1R). Similar to the IR, IGF-1R also belongs to the RTK
superfamily (De Meyts and Whittaker, 2002). IGFRs are widely
expressed throughout the central nervous system (CNS) as well
as in the majority of peripheral tissues. BRET has facilitated the
detection of the activation state of the IGF-1R, independently of
any phosphorylation event by allowing the measurement of struc-
tural changes to the receptor in response to its cognate ligand
(Blanquart et al., 2005). Activation of IGFR has been strongly
implicated in generating a protective mechanism favoring neu-
ronal cell survival and regeneration, which makes IGFR a potential
therapeutic target for treating brain ischemic injury and neurode-
generative disorders (Roudabush et al., 2000; Mattson et al., 2004b;
Harvie et al., 2011; Zemva and Schubert, 2011).
In order to evaluate the activity of IR and IGFR signaling path-
ways, both rapidly and in real-time, different BRET assays have
been optimized for multiple applications. BRET assays for the real-
time monitoring of the IR activity in living cells have been applied
to investigate the molecular nature of binding partner interac-
tions [growth factor receptor-bound protein 14, Grb14 (Nouaille
et al., 2006)], the identification of novel IR system interactors [e.g.,
Sam68 (Quintana-Portillo et al., 2012)], as well as the activation
mechanism of the IRs themselves (Boute et al., 2001). Further-
more, the BRET assay can also be applied to demonstrate or verify
poor interactions between the IR and its substrates. IR substrates
(IRS)-5 and -6 are two recently identified members of the IRS
family. With the application of the BRET assay, Versteyhe et al.
(2010) illustrated the finding that IRS-5 and IRS-6 are poor sub-
strates for the IR compared to IRS1 and Shc (Versteyhe et al.,
2010). More recently, using the BRET-2 assay in IR-Rluc8 and
IRS(1,4,5)/Shc-GFP2 co-transfected HEK293 cells, Kulahin et al.
(2012) examined interactions between IR and the canonical IRS
(IRS1, IRS4) as well as the bifunctional SH2-domain-containing
adaptor protein Shc. With this experimental paradigm, this group
was able to demonstrate that specific insulin analogs may possess
a 10-fold more potent capacity for the recruitment of IRS1, IRS4,
and Shc, compared to human insulin. These varied studies suggest
that the IR-based BRET assay may be a valuable tool to discover
molecules with insulin-like properties.
Blanquart et al. (2005, 2006) have also applied BRET assays to
pursue mechanistic questions into greater depth concerning the
conformational changes of IGFR or IR induced by negative reg-
ulators such as PTP1B. Earlier, Boute et al. (2003) described the
monitoring of the interactional dynamics of IR with PTP1B upon
insulin stimulation. In 2005, using BRET, it was demonstrated that
with insulin stimulation, the interaction of IR with receptor-like
protein tyrosine phosphatases (PTPalpha and PTPepsilon) was
due to conformational changes within preassociated IR/protein
tyrosine phosphatase complexes (Lacasa et al., 2005). Later in
2011, Boubekeur et al. (2011) showed the interaction of PTP1B
with the IR precursor during its biosynthesis in the endoplasmic
reticulum. Similar to the IR-based BRET assay, co-transfection of
Rluc or YFP-fused IGFR in HEK293 cells constitutes the ligand-
induced conformation monitoring BRET assay. Additionally, by
co-transfecting both IGF-1R-Rluc and YFP-PTP1B in HEK293
cells, the researchers were able to further reveal the interactions
between IGF-1R and the negative regulator PTP1B in response to
IGF1, IGF2, or insulin. Taken together from these varied studies,
BRET assays are a useful technique for studying ligand-induced
IR/IGFR conformational changes, assessing interactions between
IR/IGFR and their negative or positive cellular partners or modu-
lators, and setting up the platform of high-throughput screening
for leading compounds relevant to related disorders.
Recently, in 2012, BRET was used to study the effects of
insulin analogs on IR/IGF-1R hybrids. The group reported that
when using MCF-7 cells (human breast adenocarcinoma cell line),
glargine, which possibly acts via IR/IFG1R hybrids, demonstrated
higher potency while its metabolites, M1 and M2, display lower
potency than insulin for the stimulation of proliferative/anti-
apoptotic pathways (Pierre-Eugene et al., 2012). They further
developed a highly sensitive BRET-based assay that would allow
monitoring of the production of phosphatidylinositol-3 phos-
phate (PIP3) upon stimulation of endogenous IR and IGF-1R in
living cells (Pierre-Eugene et al., 2012).
BRET LABELING OF GROWTH FACTOR RECEPTORS
Bioluminescence resonance energy transfer-based techniques can
be used to either measure direct EGFR dimerization or to assess
the binding of downstream signaling factors to the activated state
of the receptor. BRET assays for EGFR have proven to be a useful
tool to study the effective pharmacology of ligand-induced inter-
action between EGFR and signaling pathway-specifying adaptor
proteins (Schiffer et al., 2007). Probing these interactions is cru-
cial as EGFR has been classified to have a central role beyond
cancer research in neurometabolic aging (Siddiqui et al., 2012)
and conditions such as asthma, where EGFR has been shown to
be upregulated in asthmatics (Amishima et al., 1998; Puddicombe
et al., 2000), and chronic obstructive lung disease (COPD) where
there is abundant mucus production, in which EGFR is known
to play a role (Takeyama et al., 1999). In vivo rodent models
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confirm the importance of EGFR in asthma (Vargaftig and Singer,
2003; Tamaoka et al., 2008; Le Cras et al., 2011). The structural
nature of the cognate ligand for EGFRs can also profoundly affect
EGFR signaling. EGFR activation by stimulants such as histamine
(Hirota et al., 2012), which does not classify with the commonly
known axis of EGFR ligands, can also be assessed using BRET.
Somatic mutations in epidermal growth factor (EGF) can produce
ligand variants that quantitatively differ in their pharmacologi-
cal and downstream signaling properties. This variability suggests
the possibility of differential clinical responsiveness to treatment
with EGFR inhibitors (Divgi et al., 1991; Perez-Soler et al., 1994;
Modjtahedi et al., 1996; Baselga et al., 2000; Robert et al., 2001;
Woodruff et al., 2010). EGFR is amongst other RTKs being probed
as potential drug targets for asthma (Siddiqui et al., 2013).
In a profound BRET-facilitated study by Tan et al. (2007), the
EGFR was shown to interact with Grb2 (growth factor receptor-
binding protein 2) as well as Shc46 (MAP kinase proliferation
pathway), PI3K-p85 regulatory subunit (PI3K-Akt survival path-
way), PLCγ1 (protein kinase C/calcium signaling pathway), and
STAT5a (from the signal transducers and activators of the tran-
scription pathway) upon stimulation with the EGF. The ErbB4
growth factor receptor has also been shown to interact with Grb2
and p85 upon stimulation with one of the various ligands able
to stimulate this receptor, i.e., heregulin-beta 1 (HRG-β1) (Tan
et al., 2007). PDGFR A and B interacted with Grb2 and PLCγ1
when platelet-derived growth factor-BB (PDFG-BB) was used as
a stimulant, while PDGFRA also interacted with p85 (Tan et al.,
2007). Employing stem cell factor (SCF)-mediated activation of
the c-Kit RTK, c-Kit was shown to dynamically interact with both
Grb2 and p85 (Tan et al., 2007). Furthermore, vascular endothelial
growth factor-C (VEGF-C) stimulation resulted in VEGFR3 and
Grb2 interaction (Tan et al., 2007).
Fibroblast growth factor receptor and Grb14 intercommunica-
tion has also been investigated with BRET (Browaeys-Poly et al.,
2010). Grb14 was found to bind to the phosphorylated FGFR
where it induces a conformational change, and thereby unmasks
a PLCγ-binding motif on Grb14, resulting in the inactivation of
PLCγ (Browaeys-Poly et al., 2010). Therefore, using BRET analysis
the authors of this study demonstrated their ability to measure the
dynamic capacity of Grb14 to functionally inhibit FGFR signal-
ing. In 2011, BRET was also used to assess the likelihood of FGFR1
homodimer formation upon stimulation by various FGF agonist
ligands in HEK293T cells (Romero-Fernandez et al., 2011). FGFR1
is activated by homodimerization when FGF agonist ligand and
heparin sulfate glycosaminoglycan are both present.
BRET LABELING OF CYTOKINE RECEPTORS
Activation of cytokine receptors by their cognate ligands induces
a rapid recruitment of the Janus family of tyrosine kinases
(Jak1/Jak2) in a Fyn- (Src-family tyrosine kinase) dependent man-
ner. In the case of cytokine receptors (e.g., growth hormone, leptin,
prolactin, or interleukin) the recruitment of the Jak kinases sub-
stitutes for the lack of an intrinsic tyrosine kinase activity in the
C-terminal domain of these receptors. Hence, the ligand-induced
association of Jak kinases with cytokine receptors in part recapitu-
lates the functional signaling behavior of EGFR-like growth factor
receptors. However, a specific function of the Jak recruitment is
their ability to tyrosine phosphorylate downstream activators of
transcription from the STAT family of proteins. The Jaks phos-
phorylate the intracellular tyrosines of the receptor complex, cre-
ating docking sites for STATs, which themselves become tyrosine-
phosphorylated, thereby forming homo- or hetero-dimeric com-
plexes that translocate to the nucleus. In the nucleus, STATs bind
to specific gene promoters to activate the transcription of a range
of targeted genes. In addition, autoinhibitory Socs (silencers of
cytokine signaling) genes are also activated by cytokine receptor
signaling via this Jak–STAT pathway (Starr et al., 1997). An assay-
based on BRET was developed to detect the dimerization and
action of the leptin receptor (OB-R), a type I cytokine receptor
(Couturier and Jockers, 2003).
The short form of the prolactin receptor inhibits prolactin-
induced activation of gene transcription by the long form of the
prolactin receptor. In 2009, it was demonstrated using BRET that
there is a higher homodimerization affinity of the mutated form of
the short form of the prolactin receptor, reduced heterodimeriza-
tion associations, long form homodimerization, and subsequent
prolactin-induced signaling (Xie et al., 2009). Recently, a new
genetically encoded biosensor based on BRET technology has been
developed to allow real-time monitoring of inflammasome activity
(Compan et al., 2012). The primary functional features of this sen-
sor are similar to the endogenous IL-1β, which makes this probe an
ideal tool for the characterization of pro-IL-1β processing and for
the high-throughput screening of compounds that may underpin
the initiation of inflammation (Compan et al., 2012).
Bioluminescence resonance energy transfer has also been suc-
cessfully applied for the study of GHR activation (Brown et al.,
2005). Along with FRET and co-immunoprecipitation in this par-
ticular study, BRET studies have generated important evidence
that GHR subunits undergo specific transmembrane interactions
independent of hormone binding (Brown et al., 2005).
USE OF BRET FOR THE STUDY OF RTK-INTERACTING
PROTEINS
In addition to investigating receptor-specific RTK events, BRET
can also be used to monitor RTK accessory protein binding. As
briefly discussed earlier, currently 22 BRET assays for 9 RTKs,
derived from 4 subfamilies [erythroblastic leukemia viral (v-erb-
b) oncogene homolog (ErbB), PDGF, neurotrophic Trk, VEGF]
have been reported that allow real-time monitoring of interac-
tions with multiple effectors, i.e., Grb2, p85, Sta5a, Shc46, PLC-γ1
(Tan et al., 2007). Demonstrating BRETs utility in this field, BRET
studies helped identify tyrosine residues 1068, 1114, 1148 as the
main residues mediating interaction of EGFR with Grb2 (Tan
et al., 2007). The use of BRET has also proven to be useful in
understanding the often complex relationships between ligand-
mediated RTK activation and sensitivity to chemical inhibitors of
their function. BRET assays have thus suggested that the con-
formational rearrangement of preformed TrkB-Shc complexes,
following BDNF-dependent activation, may prove extremely use-
ful for the HCS of potential pharmacological blockers of TrkB
signaling in a physiologically relevant context (De Vries et al.,
2010).
Furthermore, BRET has also been used to study how alpha
(v) beta (3) [α(v)β(3)] integrins cooperate with transmembrane
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FIGURE 2 | Studies assessing protein–protein interactions for RTK and
tyrosine kinase-associated receptors using Bioluminescence Resonance
EnergyTransfer (BRET). BRET assays have been established to study both
the association of multiple RTK/tyrosine kinase-interacting proteins with the
receptor superstructure as well as stimulator/inhibitor-mediated
conformational changes in receptor structure. The RTK receptors include
neurotrophic receptors (TrkA, TrkB, TrkC, p75NTR), insulinotropic receptors (IR,
IGF-1R, IR-IGF-1R hybrid receptors), and growth factor receptors (FGFR,
EGFR, ErbB4, kit, PDGFRA/B, VEGFR3). Tyrosine kinase-associated receptors
include GHR, OB-R, and integrin receptors.
receptor systems, such as tyrosine kinases, to enhance cellular
responses (Scaffidi et al., 2004). Integrins are single-pass trans-
membrane receptors for extracellular matrix proteins such as
fibronectin. While integrins themselves do not possess intrinsic
tyrosine kinase activity, upon interaction with their extracellu-
lar matrix “ligand” molecule, they rapidly associate with tyrosine
kinase scaffolding proteins such as focal adhesion kinase (FAK)
and proline-rich tyrosine kinase 2 (Pyk2) (Della Rocca et al.,
1999; Davidson et al., 2004; Maudsley et al., 2006, 2007). These
scaffolding proteins, in a similar manner to the intrinsic tyro-
sine kinase domains of growth factor receptors such as the EGFR,
upon interaction with integrin molecules activate their tyrosine
kinase catalytic function. Once this activity is stimulated, these
scaffolding proteins then undergo auto-tyrosine phosphorylation
to create signaling protein docking sites. Therefore integrin recep-
tors, as with cytokine receptors, replicate a form of classical RTK
activity.
CONCLUSION AND PERSPECTIVES
Bioluminescence resonance energy transfer is an advanced tech-
nology that can be applied in live cells and has been successfully
applied to the investigation of protein–protein interactions,
structure-function analysis, and in the mapping of signal trans-
duction pathways (e.g., RTK-interacting proteins) for RTKs and
tyrosine kinase-associated receptors (Figure 2). BRET possesses
various advantages compared to standard protein investigation
procedures that require invasive or cell-destructive processes such
as co-immunoprecipitation or even the previously developed
FRET technique. The advances made with BRET, i.e., remov-
ing the need for external energy stimulation, have also resulted
in an overall improved signal-to noise-ratio when compared to
earlier versions of the resonance energy transfer technologies.
With respect to cell signaling research, its utility has now sig-
nificantly gone beyond studying GPCRs. The use of BRET for
studying RTKs has great benefit especially as researchers con-
tinuously strive to maximize the capacity of BRET as a facil-
itator to probe for novel drugs and related signaling path-
ways. In the future, we will most likely witness an increasingly
successful number of applications and improvements to the
technology.
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